Asian Spectator


The Times

.

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

  • Written by PR Newswire Asia - Asian Spectator

SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.

In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were...

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-librarygrandpashabet giriş güncel girişgrandpashabet casino grandpashabetskorbettelegram webroyalbet girişkingroyaljojobettelegram ifşadeneme bonusubetwoonagen bolacasibomnakitbahisjojobettelegram下载jojobetjojobet